Accelerate Diagnostics and Bruker have signed a collaboration and quality agreement to validate the use of the Arc system with the MALDI Biotyper system.

The partnership aims to verify the use of Accelerate’s Arc system with Bruker’s MALDI Biotyper sirius instruments and Sepsityper software for registration in both Europe, the Middle East and Africa, and US markets.

Created for use in clinical laboratories, the Arc system streamlines workflow with an easy load-and-go process, automating the preparation of positive blood culture samples for downstream microbial identification using the MALDI Biotyper system.

The system enables processing samples as needed, eliminating the requirement for overnight culture incubation, and thereby minimising the time needed for identification results.

Laboratories can utilise the Bruker MALDI-Biotyper identification library alongside quick antibiotic susceptibility results from the Accelerate Pheno system.

Additionally, they can integrate it with the Accelerate WAVE system, currently in development and scheduled for release.

Using Bruker’s Biotyper system alongside the Arc system has the potential to decrease the chances of cross-reactivity and false positives associated with fast molecular tests.

Accelerate president and CEO Jack Phillips said: “When you think of the extreme demand that labs are under today, the Arc system is a fast and inexpensive diagnostic tool which frees up technician hands and lab budgets to deliver actionable results in the race against sepsis.

“We look forward to working with Bruker, the recognised leader in mass spectrometry-based microbial identification, to bring this much-needed solution to laboratories.”

In March last year, Accelerate introduced the Arc system for quick and accurate microbial identification of positive blood cultures.